MRK240705C148000
- 0.01
- 0.000.00%
Merck & Co Newsroom
Merck & Co Unusual Options Activity
Financial giants have made a conspicuous bearish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE:MRK) revealed 8 unusual trades.Delving into the details, we found 12% of trade
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as first-line
What Trump 2.0 or Biden 2.0 Could Mean for the Stock Market
President Biden is publicly showing no signs of stepping back and held a virtual meeting with governors on Wednesday to try to reassure them he's up to the job.
Top High Quality Stocks That Pay Dividends - UBS
Merck (NYSE:MRK) Seems To Use Debt Quite Sensibly
MRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens
Deutsche Bank's Fresh Money List for 3Q
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com
2024 Mid-Year Outlook | Wall Street Forecasts for U.S. Equities Amidst a Volatile Macroeconomic Landscape
Wall Street Forecasts for U.S. Equities Amidst a Volatile Macroeconomic Landscape.
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Merck and partner Orion Corporation announced that they have agreed to mutually exercise the option that will provide Merck global exclusive rights to develop and commercialize opevesostat (previously MK-5684)
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Broad stock market indexes like the S&P 500 hit all-time highs in the first half of 2024.The Dow Jones Industrial Average also hit all-time highs, but saw a smaller return in the first half of the yea
Overnight News: US Supreme Court made a favorable ruling on Trump's exemption rights. Federal Reserve's Williams said he still believes the Fed will bring the inflation rate back to 2%.
For more global financial news, please visit 7x24 live financial news. Market close: US stocks rose on the first day of the second half of the year, with Apple driving the Nasdaq to a historic high. In the top 20 US stock turnover on July 1st: Apple's May shipments in China increased by over 40% and the stock price hit a record high. Popular China concept stocks had mixed gains and losses on Monday, with Lixia Wei Xiaopu rising and Taiwan Semiconductor falling by 0.8%. US WTI crude oil closed up 2.3% on Monday, breaking $83 per barrel. Major European stock indexes closed higher, with the Euro Stoxx 50 up 0.74%. Macro: The US dollar jumped to a daily high as the Supreme Court rules in favor of Trump's exemption.
Health Care Up on Defensive Demands -- Health Care Roundup
Health-care companies rose as weak economic data spurred demand for defensive stocks.
Express News | Merck Shares Are Trading Higher After the Company and Orion Announced the Mutual Exercise of an Option to Convert the Companies' Ongoing Co-development and Co-commercialization Agreement for Opevesostat Into an Exclusive Global License for Merck
Market Whales and Their Recent Bets on MRK Options
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK).And retail traders should know.We noticed this today when the positions showed up on publicly available opti
Express News | Merck Shares up 3.8%
Orion Upgrades FY24 Outlook After Modifying Agreement With Merck & Co
Orion (ORNAV.HE, ORNBV.HE) upwardly revised its full-year outlook after its development and commercialization deal with US-based Merck & Co was converted into a global license for the latter, accordin
Merck, Orion Convert Collaboration Into Exclusive License
By Colin Kellaher Merck & Co. and Finland's Orion have agreed to convert a 2022 co-development and co-commercialization agreement into an exclusive global license for Merck. The companies on Monday
Express News | N-Power Medicine: Collaborates With Merck to Expand Oncologist and Patient Access to Clinical Trials
Express News | Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales...